# The European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI.

*biotech · news · 2026-05-13 · MarketScreener*

## Key points

- The European Commission approved HYMPAVZI for hemophilia A or B patients 12+ with FVIII or FIX inhibitors.
- HYMPAVZI reduced mean treated annualized bleeding rate by 93% in Phase 3 BASIS trial.
- HYMPAVZI is the first anti-TFPI approved for hemophilia and the first via pre-filled auto-injector pen.
- HYMPAVZI’s mechanism targets TFPI, not replacement factors, offering an alternative for inhibitor patients.
- For hemophilia B, HYMPAVZI is the first once-weekly subcutaneous prophylactic treatment option.

**Companies:** Pfizer Inc.
**Countries:** United States, European Union

[Read the full story on MarketScreener](https://www.marketscreener.com/news/pfizer-inc-approves-hympavzi-for-treatment-of-adults-and-adolescents-with-hemophilia-a-or-b-with-inh-ce7f5bdcd88df226)

---

Canonical: https://newsio.io/n/ffb28e3f-beeb-4396-862b-32afb43dd83e/the-european-commission-ec-has-granted-marketing-authorization-to-expand-the-app
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works